Immunitybio Stock Technical Analysis

IBRX Stock  USD 6.45  0.89  12.13%   
As of the 25th of January, Immunitybio retains the Risk Adjusted Performance of 0.1705, market risk adjusted performance of 1.75, and Downside Deviation of 4.76. Immunitybio technical analysis makes it possible for you to employ historical prices and volume momentum with the intention to determine a pattern that calculates the direction of the firm's future prices.

Immunitybio Momentum Analysis

Momentum indicators are widely used technical indicators which help to measure the pace at which the price of specific equity, such as Immunitybio, fluctuates. Many momentum indicators also complement each other and can be helpful when the market is rising or falling as compared to ImmunitybioImmunitybio's Momentum analyses are specifically helpful, as they help investors time the market using mark points where the market can reverse. The reversal spots are usually identified through divergence between price movement and momentum.

Immunitybio Analyst Consensus

Target PriceAdvice# of Analysts
11.4Strong Buy5Odds
Immunitybio current and past analyst recommendations published by a number of research institutions as well as average analyst consensus.
Most Immunitybio analysts issue ratings four times a year, at intervals of three months. Ratings are usually accompanied by a target price to helps potential investors understand Immunitybio stock's fair price compared to its market value. Analysts arrive at stock ratings after researching public financial statements of Immunitybio, talking to its executives and customers, or listening to Immunitybio conference calls.
Immunitybio Analyst Advice Details
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Immunitybio. If investors know Immunitybio will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Immunitybio listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share
(0.41)
Revenue Per Share
0.096
Quarterly Revenue Growth
4.251
Return On Assets
(0.37)
The market value of Immunitybio is measured differently than its book value, which is the value of Immunitybio that is recorded on the company's balance sheet. Investors also form their own opinion of Immunitybio's value that differs from its market value or its book value, called intrinsic value, which is Immunitybio's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Immunitybio's market value can be influenced by many factors that don't directly affect Immunitybio's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Immunitybio's value and its price as these two are different measures arrived at by different means. Investors typically determine if Immunitybio is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Immunitybio's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.

Immunitybio 'What if' Analysis

In the world of financial modeling, what-if analysis is part of sensitivity analysis performed to test how changes in assumptions impact individual outputs in a model. When applied to Immunitybio's stock what-if analysis refers to the analyzing how the change in your past investing horizon will affect the profitability against the current market value of Immunitybio.
0.00
10/27/2025
No Change 0.00  0.0 
In 3 months and 1 day
01/25/2026
0.00
If you would invest  0.00  in Immunitybio on October 27, 2025 and sell it all today you would earn a total of 0.00 from holding Immunitybio or generate 0.0% return on investment in Immunitybio over 90 days. Immunitybio is related to or competes with Arcus Biosciences, Denali Therapeutics, Cogent Biosciences, Galapagos, Beam Therapeutics, Recursion Pharmaceuticals, and Liquidia Technologies. ImmunityBio, Inc., a clinical-stage biotechnology company, engages in developing therapies and vaccines that complement,... More

Immunitybio Upside/Downside Indicators

Understanding different market momentum indicators often help investors to time their next move. Potential upside and downside technical ratios enable traders to measure Immunitybio's stock current market value against overall market sentiment and can be a good tool during both bulling and bearish trends. Here we outline some of the essential indicators to assess Immunitybio upside and downside potential and time the market with a certain degree of confidence.

Immunitybio Market Risk Indicators

Today, many novice investors tend to focus exclusively on investment returns with little concern for Immunitybio's investment risk. Other traders do consider volatility but use just one or two very conventional indicators such as Immunitybio's standard deviation. In reality, there are many statistical measures that can use Immunitybio historical prices to predict the future Immunitybio's volatility.
Hype
Prediction
LowEstimatedHigh
0.397.8516.00
Details
Intrinsic
Valuation
LowRealHigh
0.377.4315.58
Details
Naive
Forecast
LowNextHigh
0.598.7416.90
Details
5 Analysts
Consensus
LowTargetHigh
10.3711.4012.65
Details

Immunitybio January 25, 2026 Technical Indicators

Immunitybio Backtested Returns

Immunitybio is unstable given 3 months investment horizon. Immunitybio holds Efficiency (Sharpe) Ratio of 0.21, which attests that the entity had a 0.21 % return per unit of risk over the last 3 months. We were able to interpolate data for twenty-nine different technical indicators, which can help you to evaluate if expected returns of 1.73% are justified by taking the suggested risk. Use Immunitybio Downside Deviation of 4.76, market risk adjusted performance of 1.75, and Risk Adjusted Performance of 0.1705 to evaluate company specific risk that cannot be diversified away. Immunitybio holds a performance score of 16 on a scale of zero to a hundred. The company retains a Market Volatility (i.e., Beta) of 1.0, which attests to a somewhat significant risk relative to the market. Immunitybio returns are very sensitive to returns on the market. As the market goes up or down, Immunitybio is expected to follow. Use Immunitybio maximum drawdown, as well as the relationship between the skewness and day typical price , to analyze future returns on Immunitybio.

Auto-correlation

    
  0.14  

Insignificant predictability

Immunitybio has insignificant predictability. Overlapping area represents the amount of predictability between Immunitybio time series from 27th of October 2025 to 11th of December 2025 and 11th of December 2025 to 25th of January 2026. The more autocorrelation exist between current time interval and its lagged values, the more accurately you can make projection about the future pattern of Immunitybio price movement. The serial correlation of 0.14 indicates that less than 14.0% of current Immunitybio price fluctuation can be explain by its past prices.
Correlation Coefficient0.14
Spearman Rank Test-0.03
Residual Average0.0
Price Variance3.06
Immunitybio technical stock analysis exercises models and trading practices based on price and volume transformations, such as the moving averages, relative strength index, regressions, price and return correlations, business cycles, stock market cycles, or different charting patterns.
A focus of Immunitybio technical analysis is to determine if market prices reflect all relevant information impacting that market. A technical analyst looks at the history of Immunitybio trading pattern rather than external drivers such as economic, fundamental, or social events. It is believed that price action tends to repeat itself due to investors' collective, patterned behavior. Hence technical analysis focuses on identifiable price trends and conditions. More Info...

Immunitybio Technical Analysis

Indicator
Time Period
Execute Indicator
The output start index for this execution was thirty-six with a total number of output elements of twenty-five. The Average True Range was developed by J. Welles Wilder in 1970s. It is one of components of the Welles Wilder Directional Movement indicators. The ATR is a measure of Immunitybio volatility. High ATR values indicate high volatility, and low values indicate low volatility.

About Immunitybio Technical Analysis

The technical analysis module can be used to analyzes prices, returns, volume, basic money flow, and other market information and help investors to determine the real value of Immunitybio on a daily or weekly bases. We use both bottom-up as well as top-down valuation methodologies to arrive at the intrinsic value of Immunitybio based on its technical analysis. In general, a bottom-up approach, as applied to this company, focuses on Immunitybio price pattern first instead of the macroeconomic environment surrounding Immunitybio. By analyzing Immunitybio's financials, daily price indicators, and related drivers such as dividends, momentum ratios, and various types of growth rates, we attempt to find the most accurate representation of Immunitybio's intrinsic value. As compared to a bottom-up approach, our top-down model examines the macroeconomic factors that affect the industry/economy before zooming in to Immunitybio specific price patterns or momentum indicators. Please read more on our technical analysis page.
 2023 2024 2025 2026 (projected)
Interest Debt Per Share1.60.910.820.47
Revenue Per Share0.0012230.02110.0190.02

Immunitybio January 25, 2026 Technical Indicators

Most technical analysis of Immunitybio help investors determine whether a current trend will continue and, if not, when it will shift. We provide a combination of tools to recognize potential entry and exit points for Immunitybio from various momentum indicators to cycle indicators. When you analyze Immunitybio charts, please remember that the event formation may indicate an entry point for a short seller, and look at different other indicators across different periods to confirm that a breakdown or reversion is likely to occur.

Immunitybio January 25, 2026 Daily Trend Indicators

Traders often use several different daily volumes and price technical indicators to supplement a more traditional technical analysis when analyzing securities such as Immunitybio stock. With literally thousands of different options, investors must choose the best indicators for them and familiarize themselves with how they work. We suggest combining traditional momentum indicators with more near-term forms of technical analysis such as Accumulation Distribution or Daily Balance Of Power. With their quantitative nature, daily value technical indicators can also be incorporated into your automated trading systems.

Additional Tools for Immunitybio Stock Analysis

When running Immunitybio's price analysis, check to measure Immunitybio's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Immunitybio is operating at the current time. Most of Immunitybio's value examination focuses on studying past and present price action to predict the probability of Immunitybio's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Immunitybio's price. Additionally, you may evaluate how the addition of Immunitybio to your portfolios can decrease your overall portfolio volatility.